Dr Richard Armer
Scientific Advisor

Richard Armer brings significant experience from his work in both small biotechnology and large pharmaceutical companies through his roles within Pfizer, Organon, Ardana, Oxagen, Lectus Therapeutics and Redx Pharma where he served as CSO from 2014-2024. A medicinal chemist by training, Richard’s expertise is in drug discovery with a particular focus on lead optimisation activities, drug disposition, intellectual property and commercial scientific project positioning. He has experience across a wide range of therapeutic areas and has been successful in generating and progressing multiple clinical candidates including the now marketed BTK inhibitor, Pirtobrutinib.